Anti-IL1 therapy for severe FOP flare-ups
Part of Bones, joints & muscles clinical trials.
This trial is for people with FOP who have severe, frequent flare-ups. It follows those who are already starting an anti-IL1 medication (like anakinra) to see if it helps reduce flares and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with classic FOP (the R206H gene change) and are between 6 and 30 years old.
- You have frequent flare-ups—more than 4 per year—or a flare that has lasted over a month without getting better.
- Your doctor has already decided to start you on an anti-IL1 medication (like anakinra or canakinumab).
- You are able to travel to UCSF for study visits, blood draws, and scans.
- You do not have a history of unexplained infections, autoimmune disease, or a reason you cannot take anti-IL1 therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether INCB000928 can safely help people with fibrodysplasia ossificans progressiva (FOP). It mainly looks at whether the treatment is effective and well-tolerated, and it involves scheduled whole-body scans using low-dose X-rays.
This trial is a registry that collects information from people with fibrodysplasia ossificans progressiva (FOP). It helps researchers better understand the condition and use that knowledge for future studies that could lead to better care.
This study tests whether garetosmab, a new medication, can slow or stop abnormal bone formation in children with FOP (a rare condition where muscle and connective tissue gradually turn into bone). The goal is to help young people with FOP move better and have fewer joint limitations.
This study tracks the long-term safety and how well palovarotene works in people with FOP who are already taking it as part of their regular care. By joining, you help doctors learn more about the medicine over time.
This trial tests an experimental drug called AJ1-11095 for people with myelofibrosis who no longer respond to a type of JAK2 inhibitor. It aims to see if the drug can shrink the spleen, improve symptoms, and be safe.
This trial tests a new treatment called F01 for people with moderate-to-severe lupus that hasn't responded to other therapies. It aims to see if this experimental cell therapy can help control lupus symptoms when standard options have failed.
Hear when a new Fibrodysplasia Ossificans Progressiva (FOP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.